Clinical Trial Search

Primary: Time to Progression (TTP) — 164; 112 days

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants

Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants

Primary: Median Time to Progression (TTP) — 3.7 months

Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants

Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001

Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: Two Year Overall Survival — 65; 68 percentage of participants

Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s

Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Overall Survival — 289; 259 Days

Primary: Tumour Stabilisation Rate — 5.3; 16.0; 8.7 percentage of patients

Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Safety of a Combination Therapy — 0 participants

Primary: Assessment of the Dose Limiting Toxicities for the Napabucasin and Amcasertib Arm in Combination With Sorafenib for Phase IB — 0; 0; 0; 0 Dose limiting toxicities

Primary: Percentage of Participants for Each Type of Response — 0; 2.2; 5.8; 54.7 percentage of participants

Primary: Progression — 11 participants

Primary: Tumor Response — 0; 7; 47; 11 Participants

Primary: Number of Participants With Local Tumor Response According to mRECIST — 26; 0; 0; 3 Participants

Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 1; 0 Participants

Primary: Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the…